ロード中...
Pegfilgrastim Biosimilars: Where Are We Now?
In 1991, the U.S. Food & Drug Administration (FDA) approved rmetHuGCSF for human use. This recombinant methionyl human granulocyte colony-stimulating factor, or filgrastim, saw use in over 1 million patients in its first 5 years on the market. In 2002, the FDA approved a version of filgrastim wi...
保存先:
| 出版年: | J Adv Pract Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Harborside Press LLC
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8299796/ https://ncbi.nlm.nih.gov/pubmed/34430064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2021.12.5.9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|